Today's revolution in heart monitoring

7-day continuous monitoring technology significantly increases arrhythmia detection.

Choose setting, create events and manage continuous tests

Continuous monitoring, from 24 hours up to 7 days

Signal quality checked at setup of each test

Reports produced with support of Artificial Intelligence analysis

Continuous cardiac monitoring for a better arrhythmia diagnostic yield

Study show that continuous, uninterrupted external ambulatory cardiac rhythm recording, results in higher rates of cardiac arrhythmia detection. ¹

Digital Monitoring -
Features and Benefits

More accurate, more convenient, more accessible cardiovascular diagnoses.

Quoretech App Screens
Quoreone Holter Single

Wearable Device - advantages

Light - flexible - no cables;

Water resistant - patient can take shower during tests of up to 7 days;

No special electrodes;

Visual alert if electrode disconnects – protection against loss of signal;

Internal battery – no need to recharge even during 7-day test.

Digital Monitoring - advantages

Continuous monitoring, of 3 channels, over whole period – from 24 hours to 7 days;

Signal quality checked at start of each test;

Data transmitted by bluetooth;

Patient has a digital journal, improving correlation with events during tests;

Reports assisted by AI analysis.

We have solved the problem of shortfalls in arrhythmia detection rates

QuoreOne’s continuous monitoring of up to 7 days means improved diagnostic yield for atrial fibrillation – improved treatments and outcomes. ¹


- the estimated percentage of cases of atrial fibrillation not diagnosed, worldwide. ²


- the estimated increase in arrhythmia diagnoses, compared to 24-hour tests, when 7-day monitoring is used. ³ ⁴


- percentage of patients diagnosed with atrial fibrillation in 7-day monitoring, not previously diagnosed. ⁵


- increase in detection of atrial fibrillation when using ECG screening with wearable device. ⁵

1 - M. Yenikomshian, et al, Cardiac Arrhythmia Detection Monitored with Patch System, Current Medical Research and Opinion, 209, vol 35, no. 10. 1659-1670
2 – J.L. Clua-Espuny, et al, Prevalence of Undiagnosed Atrial Fibrillation and of That Not Being Treated With Anticoagulant Drugs: the AFABE Study, Rev. Esp. Cardiol. 2013: 66(7): 545-552
3 – Parikh P., et al, Diagnostic Yield of 24-hour Holter vd 7-Day and 14-Day ePatch Extended wear Holter; American College Cardiology. 2023/World Health Federation Annual Scientific Section, New Orleans, March 2023
4 – Ul-Qamar M. J., et al, Detection of unknown atrial fibrillation by prolonged ECG monitoring in all-comer patient cohort and association with clinical and Holter variables, Open Heart 2020:7: E001151. DOI:10.1136/OPENHRT-2019-001151
5- Gladstone D. J., et al, Screening for atrial fibrillation in the older population: A Rondomized Clinical Trial, JAMA Cardiol. 2021 May; 6(5): 1-10
6 - SOBRAC, A vida de um portador de arritmia cardíaca [], 10Jun2024, 19h28
7 - SBC, II Diretrizes Brasileiras sobre Fibrilação Atrial, Volume 106, nº 4, Suppl. 2, abril de 2016
8 - ANS []
9 - SUS []
10- Kim J. Y, et al, The efficacy of detecting arrhythmia is higher with 7-day continuous electrocardiographic patch monitoring than with 24-h Holter monitoring , Journal of Arrhythmia. 2023;39:422–429.
11- American Heart Association, Heart Attack and Stroke Symptoms - Arrhytmias -,11Jun2024, 13h40
12 – Paudel B., Paudel K., The Diagnostic Significance of the Holter Monitoring in the Evaluation of Palpitation, Journal of Clinical and Diagnostic Research. 2013 March, Vol-7(3): 480-483
13 – Locati E. T., et al, Role of extended external loop recorders for the diagnosis of unexplained syncope, pre-syncope, and sustained palpitations, Europace (2014) 16, 914–922
14- Joglar et al, 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation, JACC VOL. 83, NO. 1, 2024
15- Kornej J., et al Epidemiology of Atrial Fibrillation in the 21st Century, Circulation Research. 2020;127:4–20. DOI: 10.1161/CIRCRESAHA.120.316340